Sharpless: ARPA-H and NCI should help each other to “end cancer as we know it”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.

“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login